Third Harmonic Bio Inc
NASDAQ:THRD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (8.5), the stock would be worth $-7.91 (247% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -5.8 | $5.38 |
0%
|
| Industry Average | 8.5 | $-7.91 |
-247%
|
| Country Average | 13.3 | $-12.37 |
-330%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
T
|
Third Harmonic Bio Inc
NASDAQ:THRD
|
241.9m USD | -5.8 | -4.5 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
308.8B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 45 422.5 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
102.4B ZAR | 11.5 | 10.6 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
68.5B USD | -46 271.2 | 38 690 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
55.3B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
37.6B CHF | 0 | 0 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.8B USD | 41.8 | -3 284.6 | |
| US |
|
Coupang Inc
F:788
|
31.5B EUR | 20.5 | 174.3 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
30.1B ZAR | 10 | 6.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.8 |
| Median | 13.3 |
| 70th Percentile | 20.1 |
| Max | 3 188 432.5 |
Other Multiples
Third Harmonic Bio Inc
Glance View
Third Harmonic Bio Inc is a US-based company operating in industry. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2022-09-15. Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of medicine for the treatment of allergic and inflammatory diseases. Its lead product candidate, THB001, is a potent and highly selective, oral small molecule wild-type KIT inhibitor in development for the treatment of mast cell-mediated inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a range of allergic and other inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The company has completed Phase Ia clinical trial for THB001, which has demonstrated dose-dependent reductions of serum tryptase, a key biomarker of mast cell activity, which has been shown to correlate with clinical benefit in chronic urticaria patients.
